Health
ASTRAZENECA SECURES LICENSE EXTENSION AND EARLY NHS ENGLAND ACCESS TO TAGRISSOTM (osimertinib) FOR PATIENTS WITH COMPLETELY RESECTED EARLY-STAGE – PharmiWeb.com
ASTRAZENECA SECURES LICENSE EXTENSION AND EARLY NHS ENGLAND ACCESS TO TAGRISSOTM (osimertinib) FOR PATIENTS WITH COMPLETELY RESECTED EARLY-STAGE EGFR MUTATION-POSITIVE…
ASTRAZENECA SECURES LICENSE EXTENSION AND EARLY NHS ENGLAND ACCESS TO TAGRISSOTM (osimertinib) FOR PATIENTS WITH COMPLETELY RESECTED EARLY-STAGE EGFR MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER
- This is the first authorisation to be issued by the MHRA under Project Orbis.1
- AstraZeneca, NHS England and NICE have reached an agreement to enable early access to osimertinib for patients with this type of cancer, while NICE undertakes its appraisal.
- Patients with early-stage lung cancer are treated…
Continue Reading
-
Noosa News19 hours agoWoman was watching keepers work when lion attacked, Darling Downs Zoo says
-
Noosa News18 hours agoWorking for someone else made it hard to care for my daughter. So I quit
-
General22 hours agoDeveloper warns wind energy capacity may not be ready by WA coal deadline
-
Noosa News21 hours agoStar Entertainment faces $36.5m blow if Queen’s Wharf deal flops